A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 04 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.